{"id":745307,"date":"2016-11-02T16:30:00","date_gmt":"2016-11-02T16:30:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-scientists-publish-new-research-detailing-the-early-development-of-verubecestat-an-investigational-bace1-inhibitor-in-science-translational-medicine\/"},"modified":"2025-11-07T01:25:34","modified_gmt":"2025-11-07T06:25:34","slug":"merck-scientists-publish-new-research-detailing-the-early-development-of-verubecestat-an-investigational-bace1-inhibitor-in-science-translational-medicine","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-scientists-publish-new-research-detailing-the-early-development-of-verubecestat-an-investigational-bace1-inhibitor-in-science-translational-medicine\/","title":{"rendered":"Merck Scientists Publish New Research Detailing the Early Development of Verubecestat, an Investigational BACE1 Inhibitor in Science Translational Medicine"},"content":{"rendered":"<p class=\"bwalignc\">       Results of First Phase 3 Trial Anticipated in Late 2017     <\/p>\n<p>\n      Merck (NYSE: MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced the publication of research conducted by Merck<br \/>\n      scientists on the discovery and development of verubecestat, an<br \/>\n      investigational small molecule inhibitor of the enzyme beta-site amyloid<br \/>\n      precursor protein cleaving enzyme 1 (BACE1), for the potential treatment<br \/>\n      of Alzheimer\u2019s disease (AD). The research was published online in the<br \/>\n      latest edition of<i> <\/i>the peer-reviewed journal<i> Science<br \/>\n      Translational Medicine <\/i>and includes results from the Phase 1<br \/>\n      clinical trials in healthy volunteers<i> <\/i>and people with AD<i>. <\/i>The<br \/>\n      efficacy and safety of verubecestat is currently being evaluated in two<br \/>\n      pivotal Phase 3 clinical trials, EPOCH and APECS, for the treatment of<br \/>\n      mild-to-moderate AD and prodromal AD, respectively.\n    <\/p>\n<p>\n      \u201cThe development of a potential disease modifying therapy for treatment<br \/>\n      of Alzheimer\u2019s disease has long been a focus of biomedical research,\u201d<br \/>\n      said Dr. Michael Egan, vice president, clinical development<br \/>\n      neurosciences, Merck Research Laboratories. \u201cWe believe this research<br \/>\n      has the potential to contribute important evidence regarding the amyloid<br \/>\n      hypothesis, a leading scientific theory for what causes Alzheimer\u2019s<br \/>\n      disease, and we look forward to seeing the data from our ongoing Phase 3<br \/>\n      clinical trials.\u201d\n    <\/p>\n<p>\n      BACE1 is an important enzyme in the initiation of the toxic A\u03b2 peptide<br \/>\n      production in the brain. Researchers believe that sustained, selective<br \/>\n      inhibition of BACE1 leading to a significant decrease in the toxic A\u03b2<br \/>\n      peptide production is a promising means for therapeutic intervention.<br \/>\n      This hypothesis has not yet been demonstrated in clinical studies.\n    <\/p>\n<p>\n      Historically the development of selective BACE1 inhibitors with<br \/>\n      properties allowing oral absorption and the ability to cross the<br \/>\n      blood-brain-barrier to the site of action in the brain proved<br \/>\n      technically challenging. Detailed analysis of the BACE1 protein<br \/>\n      structure and function by Merck scientists over many years was used to<br \/>\n      design a series of drug-like compounds with an ability to inhibit the<br \/>\n      protein, both in vitro and in the central nervous system (CNS) of<br \/>\n      preclinical animal models. This process yielded the lead compound<br \/>\n      verubecestat. Verubecestat produced significant CNS A\u03b2 lowering in<br \/>\n      rodents and non-human primates treated for 6- to 9-months.<br \/>\n      Verubecestat\u2019s preclinical safety and tolerability profile supported its<br \/>\n      progression into human clinical testing for chronic use.\n    <\/p>\n<p>\n      Subsequent evaluation of once-daily doses of verubecestat in Phase 1<br \/>\n      studies of healthy volunteers and in people with AD for a duration of<br \/>\n      one week demonstrated significant decreases in the levels of A\u03b2 peptide<br \/>\n      production, a key marker of BACE1 activity, in the cerebral spinal fluid<br \/>\n      (CSF) of up to 80 percent. Data from patients with AD were initially<br \/>\n      presented at the 2013 <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.mercknewsroom.com%2Fpress-release%2Falzheimers-disease%2Fmerck-presents-findings-phase-1b-study-investigational-bace-inhibit&amp;esheet=51451421&amp;newsitemid=20161102006262&amp;lan=en-US&amp;anchor=Alzheimer%27s+Association+International+Conference+%28AAIC%29&amp;index=1&amp;md5=a989222d8681de84b4eaa1a151236637\" rel=\"nofollow\">Alzheimer\u2019s<br \/>\n      Association International Conference (AAIC)<\/a>.\n    <\/p>\n<p>\n      <b>Results of the Phase 1 trial of<\/b> <b>patients with Alzheimer\u2019s<br \/>\n      disease<\/b>\n    <\/p>\n<p>\n      The randomized, double-blind, placebo-controlled multiple dose study<br \/>\n      evaluated the safety and tolerability, pharmacokinetics and<br \/>\n      pharmacodynamic profile of verubecestat in patients with<br \/>\n      mild-to-moderate Alzheimer\u2019s disease (n=32). Patients were randomized to<br \/>\n      receive one of three doses (12 mg, 40 mg and 60 mg) of verubecestat or<br \/>\n      placebo orally once-daily for seven days. Samples of CSF were collected<br \/>\n      over 36 hours via a lumbar catheter and analyzed for levels of amyloid \u03b2<br \/>\n      40 (A\u03b240), amyloid \u03b2 42 (A\u03b242) and soluble amyloid precursor protein \u03b2<br \/>\n      (sAPP\u03b2) as biomarkers of BACE1 activity.\n    <\/p>\n<p>\n      In this study, verubecestat at doses of 12, 40 and 60 mg caused a<br \/>\n      dose-dependent and sustained reduction in the levels of A\u03b240 from<br \/>\n      baseline in the CSF, a measure of BACE1 activity, of 57, 79 and 84<br \/>\n      percent, respectively.\n    <\/p>\n<p>\n      No study discontinuations due to adverse events were recorded. Analysis<br \/>\n      of vital signs and laboratory assessments, including liver function<br \/>\n      tests, showed no statistically significant changes related to the<br \/>\n      administration of verubecestat.&nbsp;Verubecestat was generally<br \/>\n      well-tolerated in healthy volunteers and individuals with AD. No<br \/>\n      dose-dependent increase in the incidence of adverse events was observed.<br \/>\n      Adverse events included headache, nasal congestion and dizziness.\n    <\/p>\n<p>\n      <b>About the EPOCH Study<\/b>\n    <\/p>\n<p>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT01739348%3Fterm%3Dmk-8931%26rank%3D3&amp;esheet=51451421&amp;newsitemid=20161102006262&amp;lan=en-US&amp;anchor=EPOCH&amp;index=2&amp;md5=e216aed769ad15a66c8e11f02ccf9516\" rel=\"nofollow\">EPOCH<\/a><br \/>\n      is a Phase 2\/3 randomized, placebo-controlled, parallel-group,<br \/>\n      double-blind study evaluating efficacy and safety of two oral doses of<br \/>\n      verubecestat (12 mg and 40 mg) administered once-daily versus placebo in<br \/>\n      patients with mild-to-moderate AD currently using standard of care<br \/>\n      treatment. The primary efficacy outcomes of the study are the change<br \/>\n      from baseline in the Alzheimer&#8217;s Disease Assessment Scale Cognitive<br \/>\n      Subscale (ADAS-Cog) score, as well as the change from baseline in the<br \/>\n      Alzheimer&#8217;s Disease Cooperative Study \u2013 Activities of Daily Living<br \/>\n      (ADCS-ADL) score, following 78 weeks of treatment. For more information<br \/>\n      about the EPOCH study, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fclinical-trials%2Finfographics%2FP07738.html&amp;esheet=51451421&amp;newsitemid=20161102006262&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated%2Fclinical-trials%2Finfographics%2FP07738.html&amp;index=3&amp;md5=8eb650bc42c6fe4c793e13e350511537\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinical-trials\/infographics\/P07738.html<\/a>.\n    <\/p>\n<p>\n      <b>About the APECS Study<\/b>\n    <\/p>\n<p>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT01953601&amp;esheet=51451421&amp;newsitemid=20161102006262&amp;lan=en-US&amp;anchor=APECS&amp;index=4&amp;md5=f5d9450ceae97e7d6953699afa2b0a87\" rel=\"nofollow\">APECS<\/a><br \/>\n      is a randomized, placebo-controlled, parallel-group, double-blind Phase<br \/>\n      3 clinical trial to evaluate the efficacy and safety of verubecestat in<br \/>\n      subjects with prodromal AD. The study is designed to enroll 1,500<br \/>\n      participants. Patients will be randomized to receive placebo, or 12 mg<br \/>\n      or 40 mg verubecestat, once-daily. The primary efficacy outcome of the<br \/>\n      study is change from baseline in the Clinical Dementia Rating Scale-Sum<br \/>\n      of Boxes (CDR-SB) score following 104 weeks of treatment.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For 125 years, Merck has been a global health care leader working to<br \/>\n      help the world be well. Merck is known as MSD outside the United States<br \/>\n      and Canada. Through our prescription medicines, vaccines, biologic<br \/>\n      therapies, and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      health care through far-reaching policies, programs and partnerships.<br \/>\n      For more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=51451421&amp;newsitemid=20161102006262&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=5&amp;md5=6ca1d0a6c2288a8efd5777bdf5fb111a\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51451421&amp;newsitemid=20161102006262&amp;lan=en-US&amp;anchor=Twitter&amp;index=6&amp;md5=afa543e83f15789dd32bfe22a68a54b4\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=51451421&amp;newsitemid=20161102006262&amp;lan=en-US&amp;anchor=Facebook&amp;index=7&amp;md5=7a6871d32f5ed82982f61fc86c80900a\" rel=\"nofollow\">Facebook<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51451421&amp;newsitemid=20161102006262&amp;lan=en-US&amp;anchor=YouTube&amp;index=8&amp;md5=afc610ff15d3569a4b039fda56126701\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51451421&amp;newsitemid=20161102006262&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=9&amp;md5=6a746744d0302efacaf12f0663dd90da\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2015 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=51451421&amp;newsitemid=20161102006262&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=10&amp;md5=8aa55f4d8e87ba4ae6a56cfa32727b38\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n<img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20161102006262r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><br \/>\n<span class=\"bwct31415\"><br \/>\n<\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pam Eisele, 267-305-3558<br \/>or<br \/>Ian        McConnell, 908-740-1921<br \/>or<br \/>Investors:<br \/>Teri Loxam,        908-740-1986<br \/>or<br \/>Amy Klug, 908-740-1898     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Results of First Phase 3 Trial Anticipated in Late 2017 Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the publication of research conducted by Merck scientists on the discovery and development of verubecestat, an investigational small molecule inhibitor of the enzyme beta-site amyloid precursor protein cleaving enzyme 1 (BACE1), for the potential treatment of Alzheimer\u2019s disease (AD). The research was published online in the latest edition of the peer-reviewed journal Science Translational Medicine and includes results from the Phase 1 clinical trials in healthy volunteers and people with AD. The efficacy and safety of verubecestat is currently being evaluated in two pivotal Phase 3 clinical trials, EPOCH and APECS, for the treatment of mild-to-moderate AD and prodromal AD, respectively. \u201cThe development of a potential disease modifying therapy for treatment of Alzheimer\u2019s disease has long been a focus of biomedical research,\u201d said Dr. Michael<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289,56],"class_list":["post-745307","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Scientists Publish New Research Detailing the Early Development of Verubecestat, an Investigational BACE1 Inhibitor in Science Translational Medicine - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-scientists-publish-new-research-detailing-the-early-development-of-verubecestat-an-investigational-bace1-inhibitor-in-science-translational-medicine\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Scientists Publish New Research Detailing the Early Development of Verubecestat, an Investigational BACE1 Inhibitor in Science Translational Medicine - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Results of First Phase 3 Trial Anticipated in Late 2017 Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the publication of research conducted by Merck scientists on the discovery and development of verubecestat, an investigational small molecule inhibitor of the enzyme beta-site amyloid precursor protein cleaving enzyme 1 (BACE1), for the potential treatment of Alzheimer\u2019s disease (AD). The research was published online in the latest edition of the peer-reviewed journal Science Translational Medicine and includes results from the Phase 1 clinical trials in healthy volunteers and people with AD. The efficacy and safety of verubecestat is currently being evaluated in two pivotal Phase 3 clinical trials, EPOCH and APECS, for the treatment of mild-to-moderate AD and prodromal AD, respectively. \u201cThe development of a potential disease modifying therapy for treatment of Alzheimer\u2019s disease has long been a focus of biomedical research,\u201d said Dr. Michael\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-scientists-publish-new-research-detailing-the-early-development-of-verubecestat-an-investigational-bace1-inhibitor-in-science-translational-medicine\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:25:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-scientists-publish-new-research-detailing-the-early-development-of-verubecestat-an-investigational-bace1-inhibitor-in-science-translational-medicine\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-scientists-publish-new-research-detailing-the-early-development-of-verubecestat-an-investigational-bace1-inhibitor-in-science-translational-medicine\\\/\",\"name\":\"Merck Scientists Publish New Research Detailing the Early Development of Verubecestat, an Investigational BACE1 Inhibitor in Science Translational Medicine - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2016-11-02T16:30:00+00:00\",\"dateModified\":\"2025-11-07T06:25:34+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-scientists-publish-new-research-detailing-the-early-development-of-verubecestat-an-investigational-bace1-inhibitor-in-science-translational-medicine\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-scientists-publish-new-research-detailing-the-early-development-of-verubecestat-an-investigational-bace1-inhibitor-in-science-translational-medicine\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-scientists-publish-new-research-detailing-the-early-development-of-verubecestat-an-investigational-bace1-inhibitor-in-science-translational-medicine\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Scientists Publish New Research Detailing the Early Development of Verubecestat, an Investigational BACE1 Inhibitor in Science Translational Medicine\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Scientists Publish New Research Detailing the Early Development of Verubecestat, an Investigational BACE1 Inhibitor in Science Translational Medicine - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-scientists-publish-new-research-detailing-the-early-development-of-verubecestat-an-investigational-bace1-inhibitor-in-science-translational-medicine\/","og_locale":"en_US","og_type":"article","og_title":"Merck Scientists Publish New Research Detailing the Early Development of Verubecestat, an Investigational BACE1 Inhibitor in Science Translational Medicine - Merck.com","og_description":"Results of First Phase 3 Trial Anticipated in Late 2017 Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the publication of research conducted by Merck scientists on the discovery and development of verubecestat, an investigational small molecule inhibitor of the enzyme beta-site amyloid precursor protein cleaving enzyme 1 (BACE1), for the potential treatment of Alzheimer\u2019s disease (AD). The research was published online in the latest edition of the peer-reviewed journal Science Translational Medicine and includes results from the Phase 1 clinical trials in healthy volunteers and people with AD. The efficacy and safety of verubecestat is currently being evaluated in two pivotal Phase 3 clinical trials, EPOCH and APECS, for the treatment of mild-to-moderate AD and prodromal AD, respectively. \u201cThe development of a potential disease modifying therapy for treatment of Alzheimer\u2019s disease has long been a focus of biomedical research,\u201d said Dr. Michael","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-scientists-publish-new-research-detailing-the-early-development-of-verubecestat-an-investigational-bace1-inhibitor-in-science-translational-medicine\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:25:34+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-scientists-publish-new-research-detailing-the-early-development-of-verubecestat-an-investigational-bace1-inhibitor-in-science-translational-medicine\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-scientists-publish-new-research-detailing-the-early-development-of-verubecestat-an-investigational-bace1-inhibitor-in-science-translational-medicine\/","name":"Merck Scientists Publish New Research Detailing the Early Development of Verubecestat, an Investigational BACE1 Inhibitor in Science Translational Medicine - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2016-11-02T16:30:00+00:00","dateModified":"2025-11-07T06:25:34+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-scientists-publish-new-research-detailing-the-early-development-of-verubecestat-an-investigational-bace1-inhibitor-in-science-translational-medicine\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-scientists-publish-new-research-detailing-the-early-development-of-verubecestat-an-investigational-bace1-inhibitor-in-science-translational-medicine\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-scientists-publish-new-research-detailing-the-early-development-of-verubecestat-an-investigational-bace1-inhibitor-in-science-translational-medicine\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Scientists Publish New Research Detailing the Early Development of Verubecestat, an Investigational BACE1 Inhibitor in Science Translational Medicine"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"0f61ef62-8040-4162-b1f5-47cd17fa202b","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Merck-Scientists-Publish-New-Research-Detailing-the-Early-Development-of-Verubecestat-an-Investigational-BACE1-Inhibitor-in-Science-T-4IULP.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745307","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745307\/revisions"}],"predecessor-version":[{"id":3674716,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745307\/revisions\/3674716"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745307"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745307"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}